“…In the absence of an effective and safe vaccine for use against malaria in humans (although concerted global efforts are underway to develop such a vaccine [5,15,16,24,31,[39][40][41]44,48,49,53,57,59]), malaria control is based on the use of preventive measures (such as mosquito-reduction strategies and personal protection against mosquito bite) and the use of anti-malaria drugs (see, for instance, [20,21,32,46,47,61,63]). The use of anti-malarial drugs (such as Aralen, Chloroquine, Malaraquine and Nivaquine [6,43]) is, however, known to pose the problem of the emergence and transmission of drug-resistant malaria strain [3,6,20,32,33,43]. Such resistance is attributed to factors such as [3,6,20,32,33,43]:…”